» Articles » PMID: 21949571

Parallel Effects of β-adrenoceptor Blockade on Cardiac Function and Fatty Acid Oxidation in the Diabetic Heart: Confronting the Maze

Overview
Journal World J Cardiol
Date 2011 Sep 28
PMID 21949571
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetic cardiomyopathy is a disease process in which diabetes produces a direct and continuous myocardial insult even in the absence of ischemic, hypertensive or valvular disease. The β-blocking agents bisoprolol, carvedilol and metoprolol have been shown in large-scale randomized controlled trials to reduce heart failure mortality. In this review, we summarize the results of our studies investigating the effects of β-blocking agents on cardiac function and metabolism in diabetic heart failure, and the complex inter-related mechanisms involved. Metoprolol inhibits fatty acid oxidation at the mitochondrial level but does not prevent lipotoxicity; its beneficial effects are more likely to be due to pro-survival effects of chronic treatment. These studies have expanded our understanding of the range of effects produced by β-adrenergic blockade and show how interconnected the signaling pathways of function and metabolism are in the heart. Although our initial hypothesis that inhibition of fatty acid oxidation would be a key mechanism of action was disproved, unexpected results led us to some intriguing regulatory mechanisms of cardiac metabolism. The first was upstream stimulatory factor-2-mediated repression of transcriptional master regulator PGC-1α, most likely occurring as a consequence of the improved function; it is unclear whether this effect is unique to β-blockers, although repression of carnitine palmitoyltransferase (CPT)-1 has not been reported with other drugs which improve function. The second was the identification of a range of covalent modifications which can regulate CPT-1 directly, mediated by a signalome at the level of the mitochondria. We also identified an important interaction between β-adrenergic signaling and caveolins, which may be a key mechanism of action of β-adrenergic blockade. Our experience with this labyrinthine signaling web illustrates that initial hypotheses and anticipated directions do not have to be right in order to open up meaningful directions or reveal new information.

Citing Articles

Heart Failure and Drug Therapies: A Metabolic Review.

Yu F, McLean B, Badiwala M, Billia F Int J Mol Sci. 2022; 23(6).

PMID: 35328390 PMC: 8950643. DOI: 10.3390/ijms23062960.


Application of Animal Models in Diabetic Cardiomyopathy.

Lee W, Kim J Diabetes Metab J. 2021; 45(2):129-145.

PMID: 33813812 PMC: 8024147. DOI: 10.4093/dmj.2020.0285.


Network Pharmacology-Based Strategy Reveals the Effects of Maxim.- Compound on Oxidative Capacity and Cardiomyocyte Apoptosis in Rats with Diabetic Cardiomyopathy.

Zhang S, Yuan Z, Wu H, Li W, Li L, Huang H Biomed Res Int. 2020; 2020:8260703.

PMID: 33134388 PMC: 7591987. DOI: 10.1155/2020/8260703.


Hyperglycemia-induced cardiac contractile dysfunction in the diabetic heart.

Singh R, Waqar T, Howarth F, Adeghate E, Bidasee K, Singh J Heart Fail Rev. 2017; 23(1):37-54.

PMID: 29192360 DOI: 10.1007/s10741-017-9663-y.


Atorvastatin reduces β-Adrenergic dysfunction in rats with diabetic cardiomyopathy.

Carillion A, Feldman S, Na N, Biais M, Carpentier W, Birenbaum A PLoS One. 2017; 12(7):e0180103.

PMID: 28727746 PMC: 5519044. DOI: 10.1371/journal.pone.0180103.


References
1.
Cassina A, Hodara R, Souza J, Thomson L, Castro L, Ischiropoulos H . Cytochrome c nitration by peroxynitrite. J Biol Chem. 2000; 275(28):21409-15. DOI: 10.1074/jbc.M909978199. View

2.
Sellers D, Chess-Williams R . The effect of streptozotocin-induced diabetes on cardiac beta-adrenoceptor subtypes in the rat. J Auton Pharmacol. 2001; 21(1):15-21. DOI: 10.1046/j.1365-2680.2001.00200.x. View

3.
Finck B, Lehman J, Leone T, Welch M, Bennett M, Kovacs A . The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002; 109(1):121-30. PMC: 150824. DOI: 10.1172/JCI14080. View

4.
Gauthier C, Tavernier G, Charpentier F, Langin D, Le Marec H . Functional beta3-adrenoceptor in the human heart. J Clin Invest. 1996; 98(2):556-62. PMC: 507461. DOI: 10.1172/JCI118823. View

5.
Castro C, Ruiz F, Corrales F, Mato J . Methionine adenosyltransferase S-nitrosylation is regulated by the basic and acidic amino acids surrounding the target thiol. J Biol Chem. 1999; 274(24):17075-9. DOI: 10.1074/jbc.274.24.17075. View